...
首页> 外文期刊>Translational research: the journal of laboratory and clinical medicine >Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series.
【24h】

Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series.

机译:von Willebrand因子合成和/或生存减少导致的1型von Willebrand疾病:来自病例系列的观察结果。

获取原文
获取原文并翻译 | 示例

摘要

It may be difficult to diagnose type 1 von Willebrand disease (VWD) because of its heterogeneous and sometimes elusive nature. To evaluate the contribution of a shorter von Willebrand factor (VWF) survival in modulating VWD phenotype, the VWF half-life was assessed in 45 type 1 VWD patients using a 24-h 1-desamino-8-d-arginine vasopressin (DDAVP) test. A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance. VWF survival and clearance were normal in patients who carried nonsense mutations. The VWF-propeptide-to-VWF-antigen (VWF:Ag) ratio (VWFpp ratio) was higher in patients with a shorter VWF survival, and the values were inversely correlated with the VWF half-life (P<0.01). The response of VWF to DDAVP administration, which is useful to explore the synthesis and storage of VWF, was normal in patients with no mutations, whereas it decreased in patients with missense and nonsense mutations. Three scenarios, thus, are recognizable in type 1 VWD; one is associated mainly with a shorter survival of VWF, another is associated with its reduced synthesis and release, and a third is characterized by a combination of the two. The shorter VWF half-life found in patients with no VWF mutations suggests that mechanisms other than VWF might be involved in the pathogenesis of type 1 VWD.
机译:由于1型von Willebrand病(VWD)的异质性,有时难以捉摸,因此可能难以诊断。为了评估较短的von Willebrand因子(VWF)存活对调节VWD表型的贡献,使用24小时的1-desamino-8-d-精氨酸加压素(DDAVP)对45位1型VWD患者的VWF半衰期进行了评估。测试。在患有C1130F突变的患者中观察到较短的VWF生存期(T(1/2)消除[T(1/2)el] = 4.6 +/- 1.0h,而正常人为15.8 +/- 2.3h,P <0.0001),在那些进行了其他错义突变研究的患者中(T(1/2)el = 9.5 +/- 0.9h,P <0.02),在没有携带VWF突变的患者中(T(1/2)el = 7.0 +/- 0.7h ,P <0.001);减少主要取决于更大的VWF清除率。携带无意义突变的患者的VWF存活率和清除率正常。 VWF生存期较短的患者中,VWF-肽与VWF-抗原之比(VWF:Ag)较高(VWFpp比),且该值与VWF半衰期呈负相关(P <0.01)。 VWF对DDAVP给药的反应可用于探索VWF的合成和储存,在无突变的患者中反应正常,而在有错义和无义突变的患者中则下降。因此,在类型1 VWD中可以识别三种情况。一种主要与VWF的存活期短有关,另一种与VWF的合成和释放减少有关,第三种是两者结合的特征。在没有VWF突变的患者中发现较短的VWF半衰期表明,VWF以外的其他机制可能与1型VWD的发病机制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号